Cyclopharm Ltd has released a press release.
Cyclopharm 2018 First Half Preliminary Headline Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Cyclopharm
- CYC 2018 AGM Presentation
- Better Defining Airways Disease with Technegas
- Cyclopharm Acquires Scandinavian Distribution Business
- 40 Patient Milestone Achieved For Technegas USFDA Trial
- CYC CEO Presentation 2017 Australian Microcap Conference
Later from Cyclopharm
- Positive USFDA Meeting - Technegas sales expected in 2019
- CANM Endorses Technegas
- CYC Update - R&D Tax Incentive, USFDA, German Litigation
- Announcement of buy-back - Appendix 3C
- CYC Half Yearly Reports and Accounts
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm